RiverVest Venture Partners related stories
All articles and analysis
Securus Medical Group nets $6.5 mln in Series B financingSecurus Medical Group has raised $6.5 million in Series B financing. New investor 3X5 Special Opportunity Fund led the round with participation from RiverVest Venture Partners and the University of Michigan Investment in New Technology Startups program. In addition to the funding, the company has named Dr. Steven Girouard as president and CEO. Also, Nicholas Walrod, a principal at 3X5 Special Opportunity Fund, joins the company's board of directors. Based in Cleveland, Securus is a medical device company.
VCs embrace renewed interest in life science IPOsStrong gains by mid and large-cap biotech stocks this year have fueled a resurgence in IPOs of VC-backed life science companies
- OrbiMed Advisors Leads $45.9 Mln Series C Round for Otonomy
Otonomy said Wednesday that it has raised $45.9 million in Series C financing. The lead investor was OrbiMed Advisors. New investors Aperture Venture Partners and Osage University Partners also participated in the round as did existing investors Avalon Ventures, Domain Associates, Novo Ventures, RiverVest Venture Partners and TPG Biotech. In conjunction with the financing, OrbiMed's Chau Q. Khuong joins Otonomy's board of directors. Based in San Diego, Calif., Otonomy is a biopharmaceutical company that develops treatments for ear disorders and diseases.
- Abbot Completes Buy of IDEV Technologies from RiverVest Venture Partners
Global healthcare company Abbott said Wednesday that it has completed its $310 million acquisition of IDEV Technologies from RiverVest Venture Partners. Headquartered in Webster, Texas, IDEV is a provider of medical devices.
- Abbott Labs to Acquire RiverVest's IDEV Technologies for $310 Mln
Abbott Laboratories has agreed to acquire IDEV Technologies, a portfolio company of RiverVest Venture Partners. In accordance with the agreement, Abbott will acquire all outstanding equity of IDEV for $310 million. The transaction is expected to close by the end of the year. Headquartered in Webster, Texas, IDEV is a provider of medical devices.
- RiverVest Venture Sells IDEV Tech to Abbott Lab for $310 Mln
RiverVest Venture Partners said Monday it is selling IDEV Technologies to Abbott Laboratories for $310 million. The deal is expected to close by the end of the year. Webster, Texas-based IDEV develops next generation medical devices for interventional radiology, vascular surgery and cardiology. RiverVest said the sale represents a 2.6x gross return on $12 million invested by RiverVest, which owned IDEV shares through both its Fund I and Fund II.
- RiverVest Announces 14.5% IRR For Fund II
St. Louis-based RiverVest Venture Partners announced Friday that its second fund had delivered a 14.5% per annum net internal rate of return from inception in 2006 through the end of last year, after fees and expenses. The venture firm focuses on early-stage life science companies.
- Tryton Medical Seals $24M
Tryton Medical Inc., a developer of stents designed to treat bifurcation lesions, has raised $24 million from investors including PTV Sciences, RiverVest Venture Partners, Spray Venture Partners, and the 3x5 Special Opportunity Fund. The financing round was led by PTV Sciences. Tryton Medical is based in Durham, N.C.
- St. Louis VC firm RiverVest closes on $74m second fund
The Missouri biotech-focussed firm has beaten its previous fund by $30m.
- Allakos Closes $32M VC Round
Allakos Inc., a biotechnology company based in the San Francisco area, has raised $32 million in Series A venture financing. Novo Ventures led the round, with Alta Partners, RiverVest Venture Partners and the Roche Venture Fund also participating. As a result, Peter Moldt, partner at Novo Ventures; Robert Alexander, director at Alta Partners; and John McKearn, managing director at RiverVest Venture Partners, join the company’s board.